Monsanto the disposition of product lines unrelated to agriculture. In 1985, Monsanto acquired G. D. Searle & Company, a life sciences company that focused on pharmaceuticals, agriculture and animal health. In 1993, its Searle division filed a patent application for Celebrex, which in 1998 became the first selective COX‑2 inhibitor to be approved by the U.S. Food and Drug Administration (FDA). Celebrex became a blockbuster drug and was often mentioned as a key reason for Pfizer's acquisition of Monsanto's pharmaceutical business in 2002. In 1994, Monsanto introduced a recombinant version of bovine somatotropin, brand-named Posilac. Monsanto later sold this business to
Electricity sector in Mexico sector. However, CRE's attributions are limited since CFE (Federal Electricity Commission) and LFC (Central Light and Power) are outside its scope. The generation sector was opened to private participation in 1992. However, the "Comisión Federal de la Electricidad" (CFE), the state-owned utility, is still the dominant player in the generation sector, with two-thirds of installed capacity. As of the end of 2008, private generators held about 23 GW of generation capacity, mostly consisting of combined-cycle, gas-fired turbines (CCGFT). Private generators have to sell all their output to CFE since they are not allowed to sell directly to users. There is